Novel cardiovascular therapeutics and the risk of financial toxicity
Nat Rev Cardiol
.
2024 Jun;21(6):349-350.
doi: 10.1038/s41569-024-01010-4.
Authors
Alexander H Gunn
1
,
Akshay Pendyal
2
Affiliations
1
Department of Internal Medicine, Duke University School of Medicine, Durham, NC, USA. alexander.gunn@duke.edu.
2
Division of Cardiology, Duke University School of Medicine, Durham, NC, USA.
PMID:
38485769
DOI:
10.1038/s41569-024-01010-4
No abstract available
MeSH terms
Cardiovascular Agents* / adverse effects
Cardiovascular Agents* / economics
Cardiovascular Agents* / therapeutic use
Cardiovascular Diseases* / economics
Drug Costs
Humans
Substances
Cardiovascular Agents